Literature DB >> 29070649

Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.

Frederik Wein1, Marc A Weniger1, Benedikt Höing2, Judith Arnolds2, Andreas Hüttmann3, Martin-Leo Hansmann4, Sylvia Hartmann4, Ralf Küppers5.   

Abstract

The cellular microenvironment in classical Hodgkin lymphoma (cHL) is dominated by a mixed infiltrate of inflammatory cells with typically only about 1% Hodgkin and Reed/Sternberg (HRS) tumor cells. T cells are usually the largest population of cells in the cHL microenvironment, encompassing T helper (Th) cells, regulatory T cells (Tregs), and cytotoxic T cells. Th cells and Tregs presumably provide essential survival signals for HRS cells. Tregs are also involved in rescuing HRS cells from antitumor immune responses. An understanding of the immune evasion strategies of HRS cells is not only relevant for a characterization of the pathophysiology of cHL but is also clinically relevant, given the current treatment approaches targeting checkpoint inhibitors. Here, we characterized the cHL-specific CD4+ T-cell infiltrate regarding its role in immune evasion. Global gene expression analysis of CD4+ Th cells and Tregs isolated from cHL lymph nodes and reactive tonsils revealed that Treg signatures were enriched in CD4+ Th cells of cHL. Hence, HRS cells may induce Treg differentiation in Th cells, a conclusion supported by in vitro studies with Th cells and cHL cell lines. We also found evidence for immune-suppressive purinergic signaling and a role of the inhibitory receptor-ligand pairs B- and T-cell lymphocyte attenuator-herpesvirus entry mediator and CD200R-CD200 in promoting immune evasion. Taken together, this study highlights the relevance of Treg induction and reveals new immune checkpoint-driven immune evasion strategies in cHL. Cancer Immunol Res; 5(12); 1122-32. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 29070649     DOI: 10.1158/2326-6066.CIR-17-0325

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  12 in total

1.  Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.

Authors:  Fathima Zumla Cader; Ron C J Schackmann; Xihao Hu; Kirsty Wienand; Robert Redd; Bjoern Chapuy; Jing Ouyang; Nicole Paul; Evisa Gjini; Mikel Lipschitz; Philippe Armand; David Wu; Jonathan R Fromm; Donna Neuberg; X Shirley Liu; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2018-06-07       Impact factor: 22.113

2.  CD83 in Hodgkin lymphoma.

Authors:  Ralf Küppers
Journal:  Haematologica       Date:  2018-04       Impact factor: 9.941

3.  PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.

Authors:  Masaharu Kawashima; Joaquim Carreras; Hiroshi Higuchi; Ryutaro Kotaki; Takahiro Hoshina; Kazuki Okuyama; Naoto Suzuki; Masatoshi Kakizaki; Yuji Miyatake; Kiyoshi Ando; Masafumi Nakayama; Shinjiro Umezu; Ryouichi Horie; Yuriko Higuchi; Koko Katagiri; Susumu Goyama; Toshio Kitamura; Kenji Chamoto; Shingo Yano; Naoya Nakamura; Ai Kotani
Journal:  Leukemia       Date:  2020-02-24       Impact factor: 11.528

Review 4.  [Microenvironment in classical Hodgkin lymphoma].

Authors:  Anja Mottok
Journal:  Pathologe       Date:  2020-05       Impact factor: 1.011

Review 5.  Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.

Authors:  Eleonora Calabretta; Francesco d'Amore; Carmelo Carlo-Stella
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

Review 6.  Molecular biology of Hodgkin lymphoma.

Authors:  Marc A Weniger; Ralf Küppers
Journal:  Leukemia       Date:  2021-03-08       Impact factor: 11.528

7.  CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.

Authors:  Marika Guercio; Domenico Orlando; Stefano Di Cecca; Matilde Sinibaldi; Iolanda Boffa; Simona Caruso; Zeinab Abbaszadeh; Antonio Camera; Biancamaria Cembrola; Katia Bovetti; Simona Manni; Ignazio Caruana; Roselia Ciccone; Francesca Del Bufalo; Pietro Merli; Luciana Vinti; Katia Girardi; Annalisa Ruggeri; Cristiano De Stefanis; Marco Pezzullo; Ezio Giorda; Marco Scarsella; Rita De Vito; Sabina Barresi; Andrea Ciolfi; Marco Tartaglia; Lorenzo Moretta; Franco Locatelli; Concetta Quintarelli; Biagio De Angelis
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

8.  Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.

Authors:  Richard Greil; Lisa Pleyer; Bettina Jansko; Carmen Feierabend; Lukas Rettenbacher; Olga Stiefel; Christoph Rass; Patrick Morre; Daniel Neureiter; Sigrun Greil-Ressler
Journal:  Oncotarget       Date:  2018-04-17

9.  CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.

Authors:  Naike Casagrande; Cinzia Borghese; Lydia Visser; Maurizio Mongiat; Alfonso Colombatti; Donatella Aldinucci
Journal:  Haematologica       Date:  2018-10-11       Impact factor: 9.941

Review 10.  Immune-Checkpoint Blockade Therapy in Lymphoma.

Authors:  Ayumi Kuzume; SungGi Chi; Nobuhiko Yamauchi; Yosuke Minami
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.